Observational studyBMC infectious diseases2025
Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance.Advances in therapy · 2026Article
- Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study).Infectious diseases and therapy · 2026Article
- Neuropsychiatric Tolerability of Long-Acting Cabotegravir and Rilpivirine in People With HIV With Prior INSTI-Related CNS Toxicity: A Real-World Cohort Study.Open forum infectious diseases · 2026Article
- Impact of Delayed HIV Diagnosis and Treatment on Dementia Risk in Later Life.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough clinical trials reported a low and comparable rate of central nervous system (CNS)/neuropsychiatric (NP) disturbances among people with HIV (PWH) receiving integrase strand transfer inhibitors (INSTI) or other antiretroviral therapy (ART), higher rates of these disturbances have been reported in clinical practice. Our aim was to compare the occurrence of CNS-NP disorders in the different INSTI drugs.
methodsUsing data from the SCOLTA project, a multicenter observational study following PWH who start antiretrovirals to identify adverse events (AEs) in real-life, we performed a retrospective analysis (NEURO-INSTI) to assess incidence rates (IRs) and 95% confidence intervals (95% CI) of CNS/NP AEs and related interruptions. Observation was truncated at the first occurrence of any CNS/NP AEs, even if not causing treatment discontinuation. IRs were calculated as number of first occurrences/100 person-years follow-up (PYFU). To identify risk factors for CNS/NP AEs occurrence, a Cox regression analysis for competing risks was used (hazard ratio, HR, and 95% CI), including variables associated with the outcome at a p level < 0.20 in the univariate analysis.
resultsWe analyzed a sample of 2,922 PWH (mean age 47.2 years, 74.7% males) enrolled in raltegravir (RAL), dolutegravir (DTG), elvitegravir (EVG), and bictegravir (BIC) INSTI-cohorts since 2007. Over a median observation time of 28 months (interquartile range 14-45), 126 CNS/NP AEs and 72 related discontinuations occurred; IRs were 1.59/100 PYFU (95% CI, 1.34-1.90) and 0.91/100 PYFU (95% CI 0.72-1.15), respectively. In multivariate models, intravenous drug use history (IVDUh), current abacavir use, RAL use, and psychiatric illnesses were associated with a higher risk of CNS/NP AEs. IVDUh and current abacavir use were also associated with treatment discontinuation. Using an INSTI as a first-line therapy and starting with CD4 ≥ 350 cell/µL also increased the likelihood of discontinuation. Compared to DTG, BIC and EVG showed lower risks of CNS/NP AEs (adjusted HR 0.27, 95% CI 0.10-0.74, and 0.51, 95% CI 0.22-1.20, respectively), while RAL showed a higher risk (aHR 2.52, 95% CI 1.57-4.05).
conclusionsAmong PWH on INSTI treatment, IVDUh, concurrent psychiatric illness, abacavir and RAL use increased the risk of CNS/NP AEs occurrence. PWH on BIC were less likely to experience CNS/NP AEs and related treatment discontinuations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.